The allocation of COVID-19 vaccines and antivirals against emerging SARS-CoV-2 variants of concern in East Asia and Pacific region: A modelling study

  1. Kathy Leung
  2. Mark Jit
  3. Gabriel M Leung
  4. Joseph T Wu

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.lanwpc.2022.100389
  2. ScreenIT

    SciScore for 10.1101/2021.10.20.21265245: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    NIH rigor criteria are not applicable to paper type.

    Table 2: Resources

    Software and Algorithms
    SentencesResources
    Predicting the reduction in vaccine efficacy due to emerging VOCs: Currently, three types of vaccines are most widely used in the world, including the adenovirus vector vaccines (e.g. AZD1222 from AstraZeneca), mRNA vaccines (e.g. BNT162b2 from BioNTech) and inactivated virus vaccines (e.g. CoronaVac from Sinovac) 8.
    BioNTech
    suggested: None

    Results from OddPub: Thank you for sharing your data.

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    Our study has several limitations. First, we did not consider vaccine availability and the level of vaccine hesitancy in different populations. In Hong Kong, the low vaccine uptake among older adults is not because of limited vaccine supply but largely due to worries about vaccine safety among individuals of old age with comorbidities. Whereas for most Southeast Asian countries in the EAP region, increasing primary vaccine uptake to 90% might not be feasible in the short term. Second, our model assumed that the population was completely susceptible to SARS-CoV-2 and that there was no virus circulating before the commencement of vaccination programmes as a case study. Populations that have experienced multiple waves of COVID-19 previously might not need additional doses or antivirals. Recent studies found that natural infections with one dose of vaccines generated higher neutralizing titres and was correlated with highest efficacy against symptomatic infections and hospitalizations 29. Finally, we assumed that limited public health and social measures would be maintained after the primary and additional vaccinations, and a high starting effective reproductive number (Re = 6) of VOCs in the absence of vaccination. Gradual relaxation of public health and social measures would leave more options for the allocation strategies of vaccines and antivirals. In summary, our analyses provided support to the prioritization of increasing primary vaccination coverage. Heterologous vaccinat...

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2021.10.20.21265245v1 on medRxiv